CPI 613

Drug Profile

CPI 613

Alternative Names: Bylantra; CPI-613

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Cornerstone Pharmaceuticals; National Cancer Institute (USA); Rafael Pharmaceuticals; Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Thiophenes
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Acute myeloid leukaemia; T cell lymphoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; B cell lymphoma; Burkitt's lymphoma; Myelodysplastic syndromes; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Phase I/II Cancer
  • Phase I Colorectal cancer; Hodgkin's disease; Non-Hodgkin's lymphoma
  • No development reported Biliary cancer; Haematological malignancies

Most Recent Events

  • 13 Jul 2018 Rafael Pharmaceuticals plans clinical trials for Pancreatic cancer and Gastrointestinal cancer in Europe
  • 28 Jun 2018 Phase-II clinical trials in Burkitt's lymphoma and high-grade B-cell lymphoma (Second-line therapy or greater) in USA (IV) before June 2018
  • 28 Jun 2018 Updated efficacy data from a phase I trial in Haematological malignancies released by Rafael Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top